Citigroup maintains buy on Eris Lifesciences, raises target price to Rs 750

The brokerage has raised FY21 and FY22 estimated EPS by 2.5% and 3% respectively.ETMarkets.com|Updated: Dec 06, 2019, 08.28 AM ISTThinkStock PhotosCitigroup has maintained buy rating on Eris Lifesciences in... Read more »